These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 4141670

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Proceedings: Effect of the volume of iodine uptake on recurrence of Basedow's disease: in patients with suppression of iodine uptake due to actions of antithyroid agents].
    Nagataki S, Uchimura H, Ikeda H, Matsuzaki F, Imai Y.
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb 20; 50(2):409. PubMed ID: 4141671
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Hyperthyreosis in Basedow's disease].
    Välimäki MJ.
    Duodecim; 1998 Feb 20; 114(5):447-54. PubMed ID: 11466937
    [No Abstract] [Full Text] [Related]

  • 6. [Basedow's disease].
    Kumahara Y.
    Naika; 1965 Aug 20; 16(2):332-4. PubMed ID: 4161079
    [No Abstract] [Full Text] [Related]

  • 7. [L.A.T.S. activity during hyperthyroidism. Apropos of 143 cases of Basedow's disease].
    Letonturier P, Tourneur R, Sénécal P.
    Ann Med Interne (Paris); 1974 May 20; 125(5):463-7. PubMed ID: 4140703
    [No Abstract] [Full Text] [Related]

  • 8. [Basedow's disease. 1. Drug therapy of hyperthyroidism].
    Tourniaire J.
    Lyon Med; 1971 May 20; 18():Suppl:48-51. PubMed ID: 4105819
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Combination of low doses of 131-iodine and synthetic antithyroid agents for prolonged treatment in Basedow's disease. Apropos of 165 cases].
    Mitouze J, Jaffiol C, Baldet L, Ghachem M.
    Rev Fr Endocrinol Clin; 1972 May 20; 13(4):339-61. PubMed ID: 4122472
    [No Abstract] [Full Text] [Related]

  • 11. [Place of iodotherapy in the medical treatment of Basedow's disease].
    Gilbert-Dreyfus.
    Therapeutique; 1971 Apr 20; 47(4):347-9. PubMed ID: 4105094
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of T3-predominant Graves' disease].
    Lin LX.
    Zhonghua Yi Xue Za Zhi; 1988 Feb 20; 68(2):79-81. PubMed ID: 2457417
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Basedow's disease].
    Shizume K.
    Naika; 1971 Jun 20; 27(6):1156-8. PubMed ID: 4103929
    [No Abstract] [Full Text] [Related]

  • 18. [Basedow's disease: surgery, the choice treatment].
    Chiampo L.
    Minerva Endocrinol; 1987 Jun 20; 12(1):49-53. PubMed ID: 2438548
    [No Abstract] [Full Text] [Related]

  • 19. [Recurrence rate following thyrostatic therapy of patients with hyperthyroidism and diffuse goiter (Graves' disease). Relation to the concentration of inorganic iodine in the plasma].
    Hansen PE.
    Ugeskr Laeger; 1983 Mar 28; 145(13):980-2. PubMed ID: 6190284
    [No Abstract] [Full Text] [Related]

  • 20. The evolution of the ophthalmopathy during antithyroid drug therapy and its relationship with serum thyroglobulin and antithyroglobulin antibody in patients with Basedow's disease.
    Bromberg N, Werner RS, Sgarbi JA, Werner MC, Romaldini JH.
    Exp Clin Endocrinol; 1991 May 28; 97(2-3):354-7. PubMed ID: 1717300
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.